MA37763A1 - Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 - Google Patents

Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1

Info

Publication number
MA37763A1
MA37763A1 MA37763A MA37763A MA37763A1 MA 37763 A1 MA37763 A1 MA 37763A1 MA 37763 A MA37763 A MA 37763A MA 37763 A MA37763 A MA 37763A MA 37763 A1 MA37763 A1 MA 37763A1
Authority
MA
Morocco
Prior art keywords
hexahydro
difluoro
benzooxazinyls
cyclopentaoxazinyl
bace1 inhibitors
Prior art date
Application number
MA37763A
Other languages
English (en)
Other versions
MA37763B1 (fr
Inventor
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37763A1 publication Critical patent/MA37763A1/fr
Publication of MA37763B1 publication Critical patent/MA37763B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La présente invention concerne des difluorocyclopentaoxazinyles et des difluorobenzooxazinyles de formule (i), présentant une activité inhibitrice de bace1, leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en tant que substances actives sur le plan thérapeutique. Les composés actifs de la présente invention sont utiles dans le traitement thérapeutique et/ou prophylactique de, par exemple, la maladie d'alzheimer.
MA37763A 2012-06-26 2013-06-24 Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 MA37763B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173690 2012-06-26
PCT/EP2013/063086 WO2014001228A1 (fr) 2012-06-26 2013-06-24 Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1

Publications (2)

Publication Number Publication Date
MA37763A1 true MA37763A1 (fr) 2016-08-31
MA37763B1 MA37763B1 (fr) 2017-05-31

Family

ID=48672630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37763A MA37763B1 (fr) 2012-06-26 2013-06-24 Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1

Country Status (22)

Country Link
US (1) US9181232B2 (fr)
EP (1) EP2864324B1 (fr)
JP (1) JP6251257B2 (fr)
KR (1) KR20150023450A (fr)
CN (1) CN104470915B (fr)
AU (1) AU2013283524B2 (fr)
BR (1) BR112014029742A2 (fr)
CA (1) CA2872181A1 (fr)
CL (1) CL2014003325A1 (fr)
CO (1) CO7151509A2 (fr)
CR (1) CR20140528A (fr)
EA (1) EA025273B1 (fr)
HK (1) HK1206344A1 (fr)
IL (1) IL236138A (fr)
MA (1) MA37763B1 (fr)
MX (1) MX2014014937A (fr)
NZ (1) NZ702253A (fr)
PE (1) PE20142450A1 (fr)
PH (1) PH12014502623B1 (fr)
SG (1) SG11201407576YA (fr)
UA (1) UA113309C2 (fr)
WO (1) WO2014001228A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
WO2014134341A1 (fr) 2013-03-01 2014-09-04 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants
EP2964644B1 (fr) 2013-03-08 2018-12-26 Amgen, Inc. Composés perfluorés à base de 1,3-oxazin-2-amine condensée avec un cyclopropyle en tant qu'inhibiteurs de la bêta-secrétase et leurs procédés d'utilisation
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
WO2016022724A1 (fr) 2014-08-08 2016-02-11 Amgen Inc. Composés thiazin-2-amine fusionnée à un groupement cyclopropyle utilisés en tant qu'inhibiteurs de la bêta-secrétase et leurs procédés d'utilisation
SG11201707050VA (en) 2015-03-20 2017-10-30 Hoffmann La Roche Bace1 inhibitors
KR20210003872A (ko) 2018-04-27 2021-01-12 시오노기 앤드 컴파니, 리미티드 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.

Also Published As

Publication number Publication date
EP2864324A1 (fr) 2015-04-29
JP2015521640A (ja) 2015-07-30
EA025273B1 (ru) 2016-12-30
NZ702253A (en) 2016-06-24
UA113309C2 (xx) 2017-01-10
AU2013283524A1 (en) 2014-11-13
JP6251257B2 (ja) 2017-12-20
CR20140528A (es) 2015-01-12
AU2013283524B2 (en) 2017-03-30
IL236138A0 (en) 2015-02-01
US20150133440A1 (en) 2015-05-14
EA201590066A1 (ru) 2015-04-30
PH12014502623A1 (en) 2015-01-21
PE20142450A1 (es) 2015-01-28
WO2014001228A1 (fr) 2014-01-03
CO7151509A2 (es) 2014-12-29
MX2014014937A (es) 2015-03-09
CN104470915B (zh) 2019-07-26
PH12014502623B1 (en) 2015-01-21
BR112014029742A2 (pt) 2017-06-27
EP2864324B1 (fr) 2018-03-28
IL236138A (en) 2016-10-31
CL2014003325A1 (es) 2015-04-24
US9181232B2 (en) 2015-11-10
HK1206344A1 (en) 2016-01-08
CN104470915A (zh) 2015-03-25
KR20150023450A (ko) 2015-03-05
MA37763B1 (fr) 2017-05-31
SG11201407576YA (en) 2015-03-30
CA2872181A1 (fr) 2014-01-03

Similar Documents

Publication Publication Date Title
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA38556A1 (fr) Inhibiteurs de bace1
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA35576B1 (fr) Nouveaux composés
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MA41179A (fr) Composés inhibiteurs de parg
MA34474B1 (fr) Agonistes de gpr40
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
BR112017015474A2 (pt) inibidores de bace1
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c